Bước đầu đánh giá tác dụng điều trị thiếu máu não mạn tính của viên nang cerecaps

Abstract

Objective: To assess the therapeutic effect and the safe of "cerecaps capsules" for treating patients with chronic cerebral ischemia. Subject and method: A prospective, comparative longitudinal follow-up study on 68 patients with chronic ischemic disease treated with cerecaps capsules at the Department of Neurology - 108 Military Central Hospital from October 2016 to April 2018. Result: According to traditional medicine, patients with the highest level of damage to the body with 52.94%, the most common disease was the damage of the air with the rate of 38.23%. Drug effect improvement of the main clinical symptoms: Headache decreased 73.52%, dizziness decreased 70.58%, sleep disorders decreased 62.06% with (p<0.05). The clinical score of premenstrual hypofunction was significantly lower from 28.24 ± 2.47 to 12.48 ± 1.25. Clinical recovery was improved at a rate of 79.41%. On the REG, increasing blood flow to the brain. Electroencephalography (EEG) is indicated by an increase in both the index and the alpha wave amplitude. Cerecaps significantly lowered dyslipidemia compared with pre-treatment: Cholesterol, triglyceride, LDL-C were statistically significant (p<0.05). Cerecaps has little clinical side-effects and does not interfere with renal and hepatic function. Conclusion: Cerecaps is effective and safe in treating patients with chronic cerebral ischaemia.